<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01564095</url>
  </required_header>
  <id_info>
    <org_study_id>TOP-Study</org_study_id>
    <nct_id>NCT01564095</nct_id>
  </id_info>
  <brief_title>TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion</brief_title>
  <acronym>TOP</acronym>
  <official_title>TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Utilisation of extended criteria donors due to critical organ shortage contributes to
      increased ischemia reperfusion injury as well as mortality following liver transplantation.
      Experimental data show protective effects on hepatic ischemia reperfusion injury (IRI) using
      the calcineurin inhibitor Tacrolimus applied intravenously or directly as a hepatic rinse.
      Moreover clinical data indicate a protective role of a Tacrolimus rinse in human liver
      transplantation when using normal, healthy grafts. The effects of Tacrolimus on hepatic
      injury in extended donor criteria (EDC) liver grafts remain unclear. Therefore, the aim of
      the present study is to examine the effects of a Tacrolimus ex vivo rinse (20 ng/ml) on
      cellular injury after transplantation of marginal liver grafts exhibiting 2 or more EDCs
      according to Eurotransplant's definition of EDC grafts.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Missing evidence of the effectiveness of the study medication
  </why_stopped>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum serum ALT-level</measure>
    <time_frame>48 hrs following liver transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>1,2,4,7 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>1,2,4,7 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>1,2,4,7 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinin</measure>
    <time_frame>1,2,4,7 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Terminal Liver Disease</condition>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Graft Dysfunction</condition>
  <condition>Graft Failure</condition>
  <condition>Poor Graft Quality</condition>
  <arm_group>
    <arm_group_label>Tacrolimus + HTK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTK</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.</description>
    <arm_group_label>Tacrolimus + HTK</arm_group_label>
    <other_name>Tacrolimus, Prograf; Astellas Germany</other_name>
    <other_name>HTK, histidin-tryptophane-ketoglurate organ preservation solution, Custodiol, Dr. Franz Köhler Chemie, Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTK/Placebo</intervention_name>
    <description>Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.</description>
    <arm_group_label>HTK</arm_group_label>
    <other_name>HTK, histidin-tryptophane-ketoglurate organ preservation solution, Custodiol, Dr. Franz Köhler Chemie, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Recipient:

        Chronical terminal liver failure, age &gt; 18 years, first organ transplantation

        Donor:

          -  donor age &gt; 65 Jahre

          -  macrovesicular steatosis &gt; 40% (macroscopy or biopsy)

          -  BMI &gt; 30

          -  sodium &gt;165 mmol/l

          -  ICU stay and ventilation &gt; 7 days

          -  cold ischemia time &gt; 13 hours

          -  AST &gt; 99 U/l

          -  ALT &gt; 105 U/l

          -  bilirubin &gt; 3 mg/dl (&gt; 51 µmol/l)

          -  application of epinephrine

        Exclusion Criteria:

        Donor:

        • Hepatitis B- or Hepatitis C-infection

        Recipient:

          -  Multi organ transplantation

          -  high urgency listing

          -  extrahepatic tumor disease

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Angele, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians-University, Department of Surgery, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Pratschke, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig-Maximilians-University, Department of Surgery, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl-Walter Jauch, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwig-Maximilians-University, Department of Surgery, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General and Visceral Surgery, Johann Wolfgang Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General, Visceral and Transplantation Surgery, Ruprecht Karls University</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Transplantation Surgery, Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians University, Campus Grosshadern, Department of Surgery</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General, Visceral and Transplantation Surgery, Eberhard Karls University</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Pratschke S, Bilzer M, Grützner U, Angele M, Tufman A, Jauch KW, Schauer RJ. Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injury. J Surg Res. 2012 Jul;176(1):309-16. doi: 10.1016/j.jss.2011.07.045. Epub 2011 Aug 25.</citation>
    <PMID>21962731</PMID>
  </reference>
  <reference>
    <citation>St Peter SD, Post DJ, Rodriguez-Davalos MI, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transpl. 2003 Feb;9(2):144-9.</citation>
    <PMID>12548508</PMID>
  </reference>
  <reference>
    <citation>Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T, Mühlbacher F, Oberbauer R, Bodingbauer M. Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. Transpl Int. 2011 Sep;24(9):912-9. doi: 10.1111/j.1432-2277.2011.01284.x. Epub 2011 Jun 14.</citation>
    <PMID>21672049</PMID>
  </reference>
  <results_reference>
    <citation>Pratschke S, Arnold H, Zollner A, Heise M, Pascher A, Schemmer P, Scherer MN, Bauer A, Jauch KW, Werner J, Guba M, Angele MK. Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers. Transplant Direct. 2016 May 4;2(6):e76. doi: 10.1097/TXD.0000000000000588. eCollection 2016 Jun.</citation>
    <PMID>27500266</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Prof. Dr. M. Angele</investigator_full_name>
    <investigator_title>Prof. Dr. med. Martin Angele</investigator_title>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>EDC</keyword>
  <keyword>IRI</keyword>
  <keyword>graft survival</keyword>
  <keyword>graft function</keyword>
  <keyword>graft preconditioning</keyword>
  <keyword>Tacrolimus rinse</keyword>
  <keyword>randomised multicenter trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

